Abstract 509P
Background
Tempo-Lung trial randomly assessed the role of metronomic oral vinorelbine (OV) vs standard weekly oral vinorelbine in advanced NSCLC patients (pts) unfit to platinum doublets. Little data are available on treatment options after first-line in platinum-unfit pts.
Methods
Advanced NSCLC pts unfit to receive platinum doublets (Creatinine clearance <60 ml/min; heart failure NYHA class II-III; hearing loss >G2; any medical condition impairing platinum treatment according to physician’s opinion) were randomized to arm A (metronomic): OV 50mg x3/week (wk) or arm B (standard): OV 60 mg/m²/wk cycle 1, then 80 mg/m²/wk. Primary endpoint was progression free-survival without grade 4 toxicity (PFSG4) and secondary efficacy and safety end-point, quality of life (QoL). Data on treatment after failure of first-line vinorelbine were collected.
Results
Intention-to-treat population included 165 (arm A 83 - arm B 82) pts. Baseline characteristics were well balanced between both arms. Mean dose intensity by cycle: 73.56 mg/m²/week (arm A), 55.85 mgm²/week (arm B). Median PFSG4 significantly differ in favor of metronomic arm [95%CI]: 4.0 [2.6-4.3] vs 2.2 [1.5-2.9] months (p = 0.0068), HR [95%CI] = 0.63 [0.45-0.88]. Overall treatment related adverse events (61.4% vs 84%): haematological toxicities (27.7% vs 55.6%), G3/4 neutropenia (11% vs 42%), febrile neutropenia (3.6% vs 6.2%) and G3/4 asthenia (4.8% vs 8.6%) were reduced with metronomic OV. It was observed that 40% of patients (subset) had second line treatment: immunotherapy, chemotherapy, protein kinase inhibitor, radiotherapy. No difference was found for changes in EORTC QoL scores. Secondary endpoints will be presented.
Conclusions
Metronomic OV could be a suitable option for advanced NSCLC pts unfit to receive platinum doublets. Less toxicity was observed in metronomic arm. QoL scores were similar in both arms. A subset of platinum unfit patients could receive second-line treatment mainly consisting on immunotherapy, chemotherapy.
Clinical trial identification
2014-003859-61.
Editorial acknowledgement
We thank all Investigators, study team, nurses for their participation in the study and their support.
Legal entity responsible for the study
IRPF, Pierre Fabre Medicament.
Funding
Pierre Fabre Medicament.
Disclosure
A. Camerini: Speaker Bureau / Expert testimony, expert testimony: Pierre Fabre; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Pierre Fabre. A. Morabito: Speaker Bureau / Expert testimony, speaker bureau: Pfizer; Speaker Bureau / Expert testimony, speaker bureau: BMS; Speaker Bureau / Expert testimony, speaker bureau: MSD; Speaker Bureau / Expert testimony, speaker bureau: Roche; Speaker Bureau / Expert testimony, speaker bureau: AstraZeneca; Speaker Bureau / Expert testimony, speaker bureau: Boehringer Ingelheim. F. Grossi: Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: Novartis; Honoraria (self): Eli Lilly; Honoraria (self): Roche; Honoraria (self): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Pierre Fabre; Honoraria (self): BMS; Honoraria (self): Novartis; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): BMS; Research grant / Funding (self): MSD. R. Ramlau: Advisory / Consultancy: Roche; Advisory / Consultancy: MSD; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Novartis; Advisory / Consultancy: Boehringer Ingelheim. T-E. Ciuleanu: Advisory / Consultancy: Astellas; Advisory / Consultancy: Janssen; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Amgen; Advisory / Consultancy: Roche; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Lilly; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: MSD; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Servier; Advisory / Consultancy: A et D Pharma; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Sanofi; Travel / Accommodation / Expenses: Boehringer Ingelheim; Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: Servier; Travel / Accommodation / Expenses: Ipsen. G.L. Ceresoli: Advisory / Consultancy: Pfizer; Advisory / Consultancy: Astellas; Advisory / Consultancy: Boehringer Ingelheim. J. Bosch-Barrera: Honoraria (self): Pierre Fabre; Honoraria (self): MSD; Honoraria (self): Roche; Honoraria (self): BMS; Advisory / Consultancy: Boehringer Ingelheim. P. Landreau: Full / Part-time employment: Pierre Fabre. S. Gautier: Full / Part-time employment: Pierre Fabre. C. Ta Thanh Minh: Full / Part-time employment: Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract